Skip to main content

Table 5 Summary of median PFS of high cytogenetic risk patients with RRMM in randomized, phase 3 trials

From: Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk

Trial name High cytogenetic risk definition Arm 1 (n) Arm 2 (n) Arm 1 median PFS, months Arm 2 median PFS, months Hazard ratio (95% CI); P value
CASTOR t(4;14), t(14;16), or del17p assessed by FISH or karyotyping D-Vd (40) Vd (35) 12.6 6.2 0.41 (0.21–0.83); 0.0106
ENDEAVOR [19] t(4;14) or t(14;16) in ≥ 10% of screened plasma cells or del17p in ≥ 20% of screened plasma cells assessed by FISH Kd (97) Vd (113) 8.8 6.0 0.65 (0.45–0.92); 0.0075
ASPIRE [20] t(4;14), t(14;16), or del17p (in ≥ 60% of screened plasma cells) assessed by FISH KRd (48) Rd (52) 23.1 13.9 0.70 (0.43–1.16); 0.0829
PANORAMA-1 [21] t(4;14), t(14;16), or del17p assessed by FISH Panobinostat plus Vd Vd 0.47 (0.18–1.25)
  1. CI confidence interval, D-Vd daratumumab plus bortezomib/dexamethasone, FISH fluorescence in situ hybridization, Kd carfilzomib/dexamethasone, KRd carfilzomib/lenalidomide/dexamethasone, PFS progression-free survival, Rd lenalidomide/dexamethasone, Vd bortezomib/dexamethasone